Relay Therapeutics (RLAY) Price Target Raised to Reflect Trial Data

AI Summary

Raymond James has increased its price target for Relay Therapeutics (RLAY) based on recent clinical trial data. The new target reflects improved expectations for the company's drug candidates following updates from the trials. This adjustment may influence investor sentiment and trading volumes in RLAY shares, as the anticipated results could lead to increased market interest. Analyst revisions of price targets are important indicators of future performance and investor confidence.